| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC2902 |
| Trial ID | NCT05202561 |
| Disease | Advanced Solid Tumor |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | mRNA vaccine |
| Treatment | RNA tumor Vaccine |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Single-Arm, Open-Label, Exploratory Study to Evaluate the Safety of RNA Tumor Vaccine Injection Alone/in Combination With PD-1 Inhibitor in the Treatment of Advanced Solid Tumors With KRAS Mutation |
| Year | 2022 |
| Country | China |
| Company sponsor | First Affiliated Hospital Bengbu Medical College |
| Other ID(s) | LWY21084CBY |
| Cohort1: RNA tumor vaccine | |||||||||
|
|||||||||
| Cohort2: RNA tumor vaccine+Navuliumab | |||||||||
|
|||||||||